Novo Nordisk fellowship program

Novo Nordisk at a glanceIntroduction to the company

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership within:• diabetes care• insulin• injection devices

Thanks to dedicated research into proteins, Novo Nordisk also holds leading positions within:• haemostasis management• growth hormone therapy• hormone replacement therapy

Novo Nordisk Worldwide: > 33,000 employees

Production sites

R&D facilities Clinical development centres

Affiliates Representative offices

Regional and business area offices

SeattleBeijing

Denmark

Bangalore

Princeton

R&D locations• Copenhagen, Denmark• Beijing, China• Seattle, WA, USA• Princeton, NJ, USA• Bangalore, India

Clinical Development centres• Zürich, Switzerland• Beijing, China• Princeton, NJ, USA• Tokyo, Japan

>3800 staff today, 5000 staff in 2020Global R&D

The ability to attract talent in Denmark is key to us

81 3898 154

194

27

R&D 4354

Employees in R&D 01-Mar-2013

Additional Novo Nordisk R&D facts

• > DKK 10 billion R&D investment

• Ranked 4th out of 20 international pharmaceutical and biotech companies listed as best employers by Science Magazine

• 778 scientific publication in 2010-11 (2010 h-index: 26)

• 25 PhD and 6 post docs supported through the LIFEPHARM PhD school at University of Copenhagen focussing on pharmacology.

• ~ 100 PhD/PostDoc science students from Europe, North America and Asia

• Top rating in Dow Jones Sustainability Index for the last ten years

8Industry talent requirements and challenges

We rely on excellent talent within all our competency areas to sustain growth

E.coliYeast

Mammalian cellsPrefilled pens

Durable pens

Oral deliveryLiquid delivery

Sustained release

Subc. delivery

Amino acid substitutionAcylation Medical insight

Trial designExecution

Therapy area expertiseModification

Our core beliefs

9Industry talent requirements and challenges

INNOVATION&

GROWTH

Talents

DiversityPerformance

Fellowship Programmes

Talent Attraction

Support of Education System

Long termRelations

Knowledge Transfer

STAR PostDoc Fellows 2013Active and completed 1998 – 30 June 2013

Burnham Institut Medical Research

Clinical Medical Regulatory OfficesR&D locations

Berkley

McGill University

Loyola

Consiglio Nazionale delle Ricerche

Chapel Hill University Princeton

San Francisco University

Sigma Aldrich (SAFC)

Stanford University

Toronto University

Washington University

Vrije University

Harvard

Dublin University

Geneva University

Institute for Biomedicine and Health Science

Justus-Liebig University

Karolinska Institutet

Kings College

Linköping University

Lund University

Manchester University

Martin Luther University

Nottingham University

Santiago de Compostela University

Uppsala University

The Hebrew University-Hadassah

Setsunan University, Osaka, Japan

Tokyo University

Fudan University

Novo Nordisk STAR fellowsProfessional Qualifications

• Strong competences from active research environments

• International experience and networks

• Good publications (and PhD thesis) and/or patent applications

• Skills in new technologies

• High personal ambitions

STAR fellowship postgraduate training 2013

STAR Symposium activities

LIFEPHARMThe Novo Nordisk–LIFE In Vivo Pharmacology CentrePublic – Private – PartnershipEstablished 1/9/2010

Aim•Reinforcement of section of pharmacology and toxicology @ LIFE•Continued output of PhD candidates with ’in vivo’ expertise•Ensure the continuation of the In Vivo PhD Program

Funding •9.1 M Euro 2010-2015

• 6 mill Euros from Novo Nordisk A/S• 3.1 mill Euros from LIFE

Resources•24 PhD scholarships•5 Postdoctoral fellowships (2 years each)•Professorship in clinical pharmacology & toxicology

Framework for an InnoLIFE PhD programme07/04/23

• Novo Science Ambassadors• Novo Nordisk and Novozymes have established a team of young Novo

Scholarship recipients in order to stimulate the interest for natural and medical science in the schools.

• The ambassadors’ lectures are free and can be booked at www.formidling.dk

Novo Science Ambasadors

17Presentation title Date

Recently: Elite Post Doc programme with Oxford University

• A recruitment platform for international top talents within diabetes research

• An international platform for branding NN as a top-science employer

• A platform for on-campus recruitment activities

• A platform for expanding scientific collaboration between NN and UO

• 3-year fellowships fully funded by Novo Nordisk

Objectives Scope

18November 2013

Recently: Elite Post Doc programme with Stanford University

• A recruitment platform for international top talents within immunology research

• An international platform for branding NN as a top-science employer

• A platform for on-campus recruitment activities

• A platform for expanding scientific collaboration between NN and Stanford

• 2 to 3-year fellowships fully funded by Novo Nordisk

Objectives Scope

19November 2013

Institute for Immunity,Transplantion and Infection

Slide no 20 • •

Evaluation of Early innovation/research

New metrics for evaluation of the innovation outcome such as:

• networks created, • access to novel technology & implementation • access to important know-how & implementation

on top of the classical metrics such as: • publications, • patent applications filed, • science citations etc.

Novo Nordisk R&D career paths

• To clarify development opportunities

• To specify qualifiers for different job

types and levels

More information at novonordisk.com/careers